Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch

* Celldex Therapeutics (CLDX [https://seekingalpha.com/symbol/CLDX]) priced [https://seekingalpha.com/pr/20460246-celldex-announces-pricing-of-300-million-public-offering-of-common-stock] an underwritten public offering of ~10.3M shares at a public offering price of $29.00 per share.
* All of the shares to be sold in the offering are to be sold by Celldex.
* The underwriters have a 30-day option to purchase up to an additional ~1.55M shares.
* The company expects to receive gross proceeds from the offering of ~$300M.
* The offering is expected to close on or about April 6, 2026.
* The net proceeds will fund commercial readiness and potential U.S. launch of barzolvolimab for chronic spontaneous urticaria (CSU [https://seekingalpha.com/symbol/CSU]), if approved, alongside clinical/preclinical development of product candidates, bispecific antibody platform growth, pipeline expansion, and general corporate purposes.
* The stock price dropped about 3.5% on Thursday during pre-market trade.

MORE ON CELLDEX

* Celldex Therapeutics, Inc. (CLDX) Presents at Leerink Global Healthcare Conference 2026 Transcript [https://seekingalpha.com/article/4884664-celldex-therapeutics-inc-cldx-presents-at-leerink-global-healthcare-conference-2026]
* Celldex Therapeutics, Inc. (CLDX) Presents at TD Cowen 46th Annual Health Care Conference Transcript [https://seekingalpha.com/article/4883859-celldex-therapeutics-inc-cldx-presents-at-td-cowen-46th-annual-health-care-conference]
* Celldex Therapeutics announces public offering of common stock [https://seekingalpha.com/news/4571834-celldex-therapeutics-announces-public-offering-of-common-stock]
* Celldex surges after completing enrollments in late-stage trials for lead asset [https://seekingalpha.com/news/4556880-celldex-completes-enrollments-late-stage-program]
* Seeking Alpha’s Quant Rating on Celldex [https://seekingalpha.com/symbol/CLDX/ratings/quant-ratings]